Formulary Search
You are here : Home > Formulary Search
A to Z of Drugs : D
Show Icon and Status Keys Hide Icon and Status Keys
Icon Key
Status Key
- Capsules
- Capsules
- Capsules
- Sachets (granules)
Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.
- Tablets
- Infusion
- Oral drops
On advice from specialist
NHSE do not recommend the routine prescription of vitamins and mineral preparations, with the exceptions of patients with medically diagnosed deficiency, including those with lifelong or chronic conditions, or post surgery resulting in malabsorption (e.g. Whipple’s procedure and some other GI surgeries), calcium and vitamin D for osteoporosis, prescription-only vitamin D analogues or malnutrition. Continuing need should be reviewed on a regular basis. Not for use for prevention of deficiency
- Subcutaneous injection (sc)
- Subcutaneous injection (sc)
- Subcutaneous injection (sc)
- Subcutaneous injection (sc)
- Subcutaneous injection (sc)
- Injection
- Intravenous injection (IV)
- Intravenous injection (IV)
- Intravenous injection (IV)
- Capsules
- Injection
- Tablets
If a patient with diabetes were on insulin and on multiple other treatments, a discussion with the specialist team may be prudent prior to dapagliflozin initiation.
- Tablets
Type 2 diabetes. Trusts restrict to diabetic team initiation only.
- Tablets
Not licensed in Type 1 diabetes. Not to be initiated in new Type 1 patients. Shared care remains in place for existing patients only.
Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Tablets
Treatment should be initiated or recommended by a heart failure specialist
- Tablets
Dapagliflozin is the preferred SGLT2. Reserve combination products for patients in whom separate components are less appropriate.
- Tablets
- Tablets
- Infusion
- Intravenous injection (IV)
- Subcutaneous injection (sc)
Heamatology team only.
NOT for dialysis-induced anaemia - this is not commissoned from any Surrey Heartlands Trusts.
NHSE commissioned services only. This is NOT commissoned from any Surrey Heartlands Trusts.
- Tablets
On recommendation from specialist sleep clinics (locally at RSFT/QVH) only.
- Not Specified
- Suspension
- Tablets
- Tablets
- Tablets
- Tablets
For Transfusion-related iron overload.
Not for use in thalassemia or sickle cell - NHSE commissioned services only.
- Not Specified
NHSE commissioned services only. This is NOT commissoned from any Surrey Heartlands Trusts.
Only licensed for the NHSE commissioned indications. Therefore, not for use in Surrey Heartlands Trusts
- Not Specified
NHSE commissioned services only. This is NOT commissoned from any Surrey Heartlands Trusts.
- Subcutaneous injection (sc)
Initiation and 1st month supply by the specialist team before any request for primary care prescribing.
- Capsules
ONLY after post single anastomosis duodenal illeal bypass with sleeve (SADI-S) or duodenal switch surgery.
Prescribing by primary care on recommendation from specialist team.
- Not Specified
- Tablets
- Cream
Not assessed for inclusion on the formulary. NICE guidance is anticipated in Aug 25. Advice will be updated post-NICE.
- Capsules
- Tablets
- Capsules
Initiation and stabilisation by the specialist team for a minimum of 3 months before any request for primary care prescribing.
- Subcutaneous injection (sc)
Biosimilar - prescribe by brand.
- Subcutaneous injection (sc)
Rheumatology only in secondary care.
Restricted to use in patients for whom bisphosphonates are unsuitable.
- Cream
Use only if 1st and 2nd line have failed.
Consider if self-care appropriate.
- Cream
Use only if skin is infected. Prescribe short term only up to 4 weeks, for patients with eczema where recurrent infections are a problem.
Consider if self-care is appropriate
- Lotion
Use only if skin is infected. Prescribe short term only up to 4 weeks, for patients with eczema where recurrent infections are a problem.
Consider if self-care is appropriate
- Intravenous infusion
- Subcutaneous injection (sc)
For Transfusion-related iron overload.
Not for use in thalassemia or sickle cell - NHSE commissioned services only.
- Not Specified
NHSE commissioned services only. This is NOT commissoned from any Surrey Heartlands Trusts.
- Inhalation
- Tablets
- Oral solution
- Tablets
Prescribe generically.
Initiation in Primary Care on recommendation from the specialist team.
- Sublingual tablets
Prescribe generically.
Initiation in Primary Care on recommendation from the specialist team.
- Oral lyophilisates
Note - In Primary Care, sublingual tablets are lower cost than oral lyophilisates. Consider the use of sublingual tablets if appropriate.
Initiation in Primary Care on recommendation from the specialist team.
- Nasal spray
10mcg nasal spray.
Initiation in Primary Care on recommendation from the specialist team.
- Injection
4mcg/ml injection.
- Injection
For haemophilic / von Willebrand patients undergoing surgery / following trauma.
Available as:
4mcg/ml (DDAVP)
15mcg/ml (Octim) - much more expensive. Useful when lower volume is required
- Tablets
Initiation in Primary Care on recommendation from the specialist paediatric team.
Prescribe generically.
- Sublingual tablets
Initiation in Primary Care on recommendation from the specialist paediatric team.
Prescribe generically.
- Oral lyophilisates
Initiation in Primary Care on recommendation from the specialist paediatric team.
Note - In Primary Care, sublingual tablets are lower cost than oral lyophilisates. Consider the use of sublingual tablets if appropriate.
- Oral lyophilisates
Initiation and 1 month supply by the specialist before any request for primary care prescribing.
Women - 25mcg dose
Men - 50mcg dose
- Tablets
NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.
Prescribe generically - not to be prescribed by brand.
12 hour missed pill window with higher risk of irregular bleeding
Option for endometriosis
- Not Specified
NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.
Desorex, Zelletta, Feanolla, Cerelle, Desomono, Cerazette, Lovima -Do NOT prescribe by brand
- Tablets
- Intramuscular injection (IM)
- Subcutaneous injection (sc)
- Tablets
On recommendation of palliative care team
- Tablets
- Oral solution
- Injection
- Tablets
Recommended in NICE NG191
- Intravitreal implant
- Eye drops
- Eye drops (preservative free
- unit dose)
- Oral solution
- Tablets
- Injection
- Intramuscular injection (IM)
- Subcutaneous injection (sc)
- Tablets
On advice from palliative care specialist team.
- Oral solution
- Tablets
- Injection
- Injection
- Tablets
- Intramuscular injection (IM)
- Subcutaneous injection (sc)
- Tablets
On recommendation of palliative care team
- Subconjunctival injection
- Intravitreal implant
- Intramuscular injection (IM)
- Subcutaneous injection (sc)
- Tablets
On advice from palliative care specialist team.
- Intravitreal implant
- Intra-articular injection
- Ear drops
- Spray
- Eye drops
- Eye ointment
- Eye drops
- Oral solution
- Tablets
Adult ADHD - to be diagnosed, initiated and stabilised on ADHD medication by a SABP specialist before shared-care can be requested.
See PAD entry for current shared care document "CNS stimulants in ADHD shared care - May 2016"
Patients transitioning from children's services can continue to be managed under existing arrangements
General principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral solution
- Tablets
Stable patients (cohort 1) = BLUE (with specialist team initiation) where:
- open-access discharge has been accepted by GP practice under the LCS from SABPFT.
- and the treatment is stabilised, prior to transfer of care.
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 1), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral solution
- Tablets
Patients currently receiving specialist treatment for other mental health or neurological comorbidities (cohort 2) = AMBER (shared care)
Where a GP practice has not signed up to the LCS or a patient does not meet the criteria in the LCS (cohort 2), those patients will remain under shared care.
See here for ADHD shared care agreements (LCS and non-LCS)
General principles for shared care can be found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136
- Oral solution
- Tablets
Complex patients (cohort 3) = Red (will remain with the specialist service)
- Tablets
RSFT only
- Intranasal administration
- Solution for injection
Off-label use intranasally.
SASH:
- Premedication prior to induction of general anaesthesia in patients aged 1 to 18 years of age.
- Conscious sedation of paediatric patients aged 1 to 18 years of age undergoing neuro-imaging or painless procedure.
RSFT: Conscious sedation of paediatric patients aged 1 to 18 years of age undergoing painful or painless procedures.
- Intravenous infusion
RSCH: Restricted - ICU consultant approval only
- Intravenous infusion
- Intravenous infusion
- Oral solution
- Oral suspension
- Powder
Prescribe on advice from specialist e.g. dietitian
- Not Specified
- Injection
- Injection
Restricted to Drugs & Alcohol Service.
Home office approval only.
- Injection
SASH - for patients who are nil-by-mouth.
- Oral solution
- Tablets
For short term use only
Do not offer a benzodiazepine for the treatment of any anxiety disorder in primary or secondary care except as a short-term measure (2-4 weeks) during crises. Follow the advice in the BNF on the use of a benzodiazepine in this context.
Avoid in the elderly
Beware of MHRA advice on coprescribing of benzodiazepines and opioid and risk of death.
- Injection
For short term use only
Do not offer a benzodiazepine for the treatment of any anxiety disorder in primary or secondary care except as a short-term measure (2-4 weeks) during crises. Follow the advice in the BNF on the use of a benzodiazepine in this context.
Avoid in the elderly
Beware of MHRA advice on coprescribing of benzodiazepines and opioid and risk of death.
For severe acute anxiety
- Enema
- Tablets
- Injection
- Tablets
- Oral solution
- Tablets
- Injection
- Rectal solution
- Injection
- Oral solution
Paediatric use.
Always used in combination with chlorothiazide.
- Capsules
Unlicensed product
- Tablets
- Oral suspension
- Gel
Diclofenac sodium 3% gel.
- Gel
- Suppositories
- Injection
- Tablets
- Modified release capsules
- Modified release tablets
- Eye drops
- Eye drops (preservative free
- unit dose)
- Not Specified
- Dispersible tablets
- Tablets
- Not Specified
To be initiated and first 6 months treatment to be supplied by a specialist
- Tablets
NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.
Not recommended for new initiations. Existing patients may remain on this brand.
- Tablets
Combined hormonal contraceptives - used for a variety of disorders including uterine fibroids, menopausal symptoms, endometriosis, dysmenorrhoea, menorrhagia. Off-label use for some indications - see SPC
Not recommended for new initiations. Existing patients may remain on this brand.
- Tablets
Initiation and 1st month supply by the specialist team before any request for primary care prescribing.
- Injection
Pruritus (associated with chronic kidney disease in patients on haemodialysis)
Not on Surrey Heartlands Trust formularies. Trusts with renal centres (locally this is Epsom, Frimley & Brighton) will retain prescribing responsibility’.
- Elixir
- Tablets
- Injection
- Oral solution
- Tablets
- Intravenous infusion
- Oral solution
- Tablets
- Modified release tablets
- Cream
- Ointment
- Modified release capsules
- Modified release tablets
- Modified release tablets
- Modified release capsules
- Capsules
Relapsing-remitting multiple sclerosis
- Not Specified
- Injection
- Pessaries
- Vaginal gel
- Intravenous infusion
- Oral solution
- Tablets
- Subcutaneous injection (sc)
- Cream
Use only if 1st and 2nd line light creams have failed.
Consider if self-care appropriate.
- Modified release capsules
Not 1st-line. Alternative to clopidogrel and aspirin
- Modified release capsules
- Oral suspension
- Tablets
- Capsules
Relapsing-remitting multiple sclerosis
- Sachets
On advice of stoma nurse only. Up to two boxes per month only
ABSORB ODOUR NEUTRALISING ABSORBENT GEL
- Sachets
On advice of stoma nurse only. Up to two boxes per month only
TRIO PEARL SACHETS
- Sachets
On advice of stoma nurse only. Up to two boxes per month only
ESENTA DIAMOND SACHETS
- Eye drops
- Capsules
- Modified release tablets
- Tablets
- Intravenous infusion
Inotropic support and shock.
- Enema
- Capsules
- Oral solution
- Ear drops
- Oromucosal spray
Oralvac Compact
- Subcutaneous injection (sc)
Clustek
- Tablets
- Oral suspension
- Tablets
- Oral suspension
- Tablets
- Oral suspension
- Tablets
- Oral suspension
- Tablets
- Tablets
- Oral suspension
- Tablets
- Oral suspension
- Tablets
- Oral suspension
- Tablets
- Oral suspension
- Tablets
- Oral suspension
- Tablets
- Tablets
- Intravenous infusion
This drug has not yet been assessed for formulary status.
If a patient is accessing non-NHS supplies of this medication, refer to the NHSE information here (for a similar drug called lecanemab) which provides advice on potential adverse effects.
- Oral solution
- Oro-dispersible tablets
- Tablets
Suitable for primary care prescribing on recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Not Specified
- Oral solution
- Oro-dispersible tablets
- Tablets
In Lewy Body dementia. Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Oral solution
- Oro-dispersible tablets
- Tablets
In Parkinson's dementia. Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Oral solution
- Oro-dispersible tablets
- Tablets
ONLY if co-morbid dementia (Alzheimer's, Parkinson's dementia, Lewy Body). Off-label use.
On recommendation from the mental health specialist team in patients who may or may not require ongoing follow-up from the specialist service.
Reserve oral solution and orodispersible tablets for patients who are unable to swallow tablets.
- Not Specified
- Intravenous infusion
Cardiogenic shock
- Nebules
- Nebules
For intrapleural use.
- Eye drops
- Eye drops
- Eye drops (preservative free
- unit dose)
- Not Specified
Not for initiation in new patients.
Existing patients may remain on therapy providing cardiac risk and toxicity has been considered. It is advised that patients who present with deterioration of mental health may require a review by the specialist.
- Not Specified
- Gel
Use only if 1st and 2nd line gels have failed. Consider if self-care is appropriate.
- Gel
Use only if 1st and 2nd line gels have failed. Consider if self-care is appropriate.
- Injection
- Immediate release tablets
- Modified release tablets
- Immediate release tablets
- Modified release tablets
- Capsules
100mg capsules.
- Capsules
- Dispersible tablets
- Tablets
Non-formulary.
Prophylaxis of malaria is not to be prescribed on the NHS.
- Capsules
- Dispersible tablets
- Tablets
- Capsules
ONLY for scarring alopecia or central centrifugal cicatricial alopecia
- Injection
- Gastro-resistant tablets
- Tablets
Cardiology only
- Injection
- Tablets
NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.
- Tablets
- Tablets
NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.
Not recommended for new initiations. Existing patients may remain on this brand.
- Tablets
Combined hormonal contraceptives - used for a variety of disorders including uterine fibroids, menopausal symptoms, endometriosis, dysmenorrhoea, menorrhagia. Off-label use.
Not recommended for new initiations. Existing patients may remain on this brand.
- Not Specified
- Subcutaneous injection (sc)
- Capsules
- Capsules
- Capsules
- Capsules
- Powder
Prescribe on advice from specialist e.g. dietitian
- Not Specified
- Subcutaneous injection (sc)
Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.
Not assessed for inclusion on the formulary. Contact pharmacy team for advice on making an application.
- Subcutaneous injection (sc)
- Capsules
- Tablets
This drug has not been assessed for inclusion on the formulary. Please contact your pharmacy team for advice.
- Tablets
This drug has not been assessed for inclusion on the formulary. Please contact your pharmacy team for advice.